Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Up 2.2% – Should You Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHYGet Free Report)’s share price traded up 2.2% on Thursday . The stock traded as high as $11.43 and last traded at $11.2260. 2,130 shares were traded during trading, a decline of 79% from the average session volume of 9,933 shares. The stock had previously closed at $10.98.

Santen Pharmaceutical Price Performance

The firm’s 50-day simple moving average is $10.33 and its two-hundred day simple moving average is $10.65.

Santen Pharmaceutical Company Profile

(Get Free Report)

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.

Featured Articles

Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.